Eli Lilly's retatrutide recorded a greater reduction in glycaemic haemoglobin (A1C) and more than double the weight loss effect in clinical…

Korean Alpha EN (@korean_alpha_en), Oct 28, 2026, 10:51 UTC

Eli Lilly's retatrutide recorded a greater reduction in glycaemic haemoglobin (A1C) and more than double the weight loss effect in clinical trials compared directly to the highest approved dose of ogempic.

The excerpt is quoted from a public Telegram channel, which owns its text.

Read the original post on Telegram

More posts from Korean Alpha EN · All channels